Subsequent tumor methylation profiling performed at the National Institutes of Health matched with high confidence to the class "IDH glioma, subclass astrocytoma" and confirmed lack of MGMT promoter hypermethylation. The gene discussed is IDH2; the disease is central nervous system cancer.